Synthesis of biologically active chemical compounds for drug discovery and chemical biology offered by Lithuanian biotech company for manufacturing or commercial agreements

Summary

Lithuanian biotech SME is an innovative company which provides services of chemical synthesis of novel or known chemical compounds. The chemical molecules can be used for drug discovery, building blocks for molecular architectures or applied in chemical biology. Partners in biotechnology, pharmacology and agrochemistry, who are in need of either new or known molecular structures, are sought for manufacturing or commercial agreements with technical assistance.

Description

The biotech SME is a spin-off of a life-sciences university. It is a multidisciplinary enterprise employing specialists in the fields of medicinal chemistry, synthetic chemistry, computational chemistry, analytical chemistry, robotics, mechanical engineering and computer programming. Staff's mastery in the synthesis of molecules allows for the discovery of new, biologically active molecules. The staff also develops tools for the laboratory with the aim to automate and robotize the workflow. The mission of the SME is to robotize the synthesis and purification processes in order to boost productivity thus speeding R&D processes.

The SME is offering its laboratory services where new synthesis processes and new biologically active molecules are being discovered. The focus of the laboratory is on the synthesis of novel molecules and their purification, however, upscale services for production of large amount (kilo lab) is also available. Novel molecules produced by SME can potentially be used for drug discovery, as building blocks for molecular architectures or applied in chemical biology. Among the different varieties of chemical products there are fluorinated and boronic acid heterocycles; heterocyclic metabolites and prodrugs. The excellence of the laboratory lies in its multidisciplinarity and staff experience: specialists work on chemical synthesis, simulation, purification, analysis and automation. The laboratory already contains an abundant library of reagents of about 12000 different reagents. The totality of equipment, human resources and competencies result in the potential to rapidly build screening libraries.

The chemical compounds are purified, the impurities are identified and the purity is analysed using chromatography, mass spectrometry and spectroscopy techniques. The purity of 99,9% can be achieved. In particular, the laboratory is equipped with instruments capable of performing reaction monitoring and purity determination with liquid or gas chromatography methods coupled with quadruple-time-of-flight mass spectrometry, triple quadrupole mass spectrometry in variety ionization modes. In addition, thin layer chromatography coupled with mass spectrometry, Fourier-transform infrared spectroscopy, nuclear magnetic resonance spectroscopy is performed for composition analysis. Also, a preparative purification is performed using prepHPLC systems in normal or reverse phase mode.

The laboratory also employs In Silico simulation techniques which are used for the modelling of molecular docking, structure-activity relationship, quantitative structure-activity relationship, computational activity prediction, compounds absorption, distribution, metabolism, and excretion.

For the purpose of the synthesis automation, the laboratory is designing and building an automated, robotized system animated by artificial intelligence. The prototype stage allows for 24/7 non-stop workflow and error-free task execution. The further training of artificial intelligence and development of mechanical tools will enable the synthesis and purification of new molecules automatically.

The partners and clients of the SME are companies in biotechnology, pharmacology, agrochemistry who are in need of either new or known molecular structures. The laboratory offers a service to discover and develop synthesis processes for either new or known molecules in general. The types of partnership envisioned are either manufacturing agreement or commercial agreement with technical assistance. The manufacturing agreement would mean that the SME is offering its innovative manufacturing capacities. The laboratory discovers, develops, optimizes and scales up the synthesis of known or new molecules and provides the product to a client. The commercial agreement with technical assistance would mean that the SME develops specific synthesis processes are transfers those processes to client laboratories.

Stage of Development

Already on the market

Requested Partner

The partners sought are companies in biotechnology, pharmacology, agrochemistry or similar who are in need of either new or known molecular structures. The types of partnership envisioned are either manufacturing agreement or commercial agreement with technical assistance. The manufacturing agreement would mean that the SME is offering its innovative manufacturing capacities: the laboratory discovers, develops, optimizes and scales up the synthesis of known or new molecules and provides the product to a client. The commercial agreement with technical assistance would mean that the SME develops specific synthesis processes are transfers those processes to client laboratories.